Samia Hussein

Dr. Samia Hussein

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Cytotherapy
Verified
Journal Article
Closed access
SASomia H. Abd-Allah
Somia H. Abd-Allah
SSSally M. Shalaby
Sally M. Shalaby
AEAmal S. El-Shal
Amal S. El-Shal
EEEman Abd Elkader
Eman Abd Elkader
SHSamia Hussein
Samia Hussein
MAMha Atfy
Mha Atfy

28 January 2021 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
IEImam M. Esmayel
Imam M. Esmayel
SHSamia Hussein
Samia Hussein
EGEhab A. Gohar
Ehab A. Gohar
HEHuda F. Ebian
Huda F. Ebian
MMMayada M. Mousa
Mayada M. Mousa

1 December 2017 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
MMMohamed S. Mohamed
Mohamed S. Mohamed
AHAmr S Hanafy
Amr S Hanafy
MBMohamed A.A. Bassiony
Mohamed A.A. Bassiony
SHSamia Hussein
Samia Hussein
Background and aims: Interferon-free direct-acting antivirals (DAA) combination therapies, including sofosbuvir (SOF) and daclatasvir (DCV) therapy, eradicate chronic hepatitis C virus (HCV) in a high percentage of patients, but its impact on improvements in liver function is unclear. The aim of this study was to investigate the changes in clinical and biochemical parameters reflecting liver function and general status in those who achieved HCV eradication by DAA. Patients and methods: From March 2016 to October 2016, 374 chronic hepatitis C patients were enrolled for this prospective, observational study and received SOF, DCV with ribavirin, to evaluate the changes in liver function parameters, international normalized ratio, complete blood count, model for end-stage liver disease, and Child–Turcotte–Pugh scores after achieving a sustained virological response 12 weeks after treatment. Results: In those who achieved HCV clearance, liver function parameters, serum albumin, bilirubin, platelet count, and international normalized ratio improved significantly in the majority of patients; the reduction in the model for end-stage liver disease score was (−2.36, SE 0.15, P<0.001). 44% of the patients showed an improved Child–Turcotte–Pugh score, 51% showed no change, and only 5% showed deterioration. Conclusion: Successful HCV eradication by DAAs including SOF, DCV with ribavirin therapy improved liver function parameters and clinical outcomes in chronic hepatitis C patients.

5 March 2017 in IUBMB Life
Verified
Journal Article
Closed access
PDF file
AFAnan Fathi
Anan Fathi
HMHala Mosaad
Hala Mosaad
SHSamia Hussein
Samia Hussein
MRMona Roshdy
Mona Roshdy
EIEman I. Ismail
Eman I. Ismail

19 June 2017 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
SASomia H. Abd Allah
Somia H. Abd Allah
SHSamia Hussein
Samia Hussein
MHMai M. Hasan
Mai M. Hasan
RDRaghda H. A. Deraz
Raghda H. A. Deraz
WHWafaa F. Hussein
Wafaa F. Hussein
LSLaila M. E. Sabik
Laila M. E. Sabik

5 February 2017 in IUBMB Life
Verified
Journal Article
Closed access
PDF file
EMEman M. Mohamed
Eman M. Mohamed
SAShaimaa A. Abdelrahman
Shaimaa A. Abdelrahman
SHSamia Hussein
Samia Hussein
SSSally Mahmoud Shalaby
Sally Mahmoud Shalaby
HMHala Mosaad
Hala Mosaad
AAAhmed M. B. Awad
Ahmed M. B. Awad